menu
    • menu
    [{"orgOrder":0,"company":"Flashpoint Therapeutics","sponsor":"Beta Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Flashpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Flashpoint Therapeutics \/ Beta Lab","highestDevelopmentStatusID":"4","companyTruncated":"Flashpoint Therapeutics \/ Beta Lab"},{"orgOrder":0,"company":"Flashpoint Therapeutics","sponsor":"KAIMRC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"FLASH-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Flashpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flashpoint Therapeutics \/ KAIMRC","highestDevelopmentStatusID":"7","companyTruncated":"Flashpoint Therapeutics \/ KAIMRC"}]

    Find Clinical Drug Pipeline Developments & Deals by Flashpoint Therapeutics

    Menu

    Flashpoint Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Flashpoint Therapeutics

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed

                            Flashpoint Therapeutics

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FLASH-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : KAIMRC

                            Deal Size : $50.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Flashpoint Therapeutics Announces $50M KAIMRC Partnership and Clinical Pipeline Expansion

                            Details : The partnership aims for the development of FLASH-001, a structural nanomedicine incorporating toll-like receptor 9 agonists for immuno-oncology applications.

                            Product Name : FLASH-001

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 14, 2024

                            Lead Product(s) : FLASH-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : KAIMRC

                            Deal Size : $50.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Flashpoint Therapeutics

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed

                            Flashpoint Therapeutics

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Beta Lab

                            Deal Size : $10.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Flashpoint Therapeutics Announces $10M Seed Financing Led by Beta Lab to Pioneer Nanotechnology-Enabled Medici...

                            Details : The funding will be used to advance company's first therapeutic candidate in oncology, nominate a second development candidate, and advance multiple internal and partnered discovery programs.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 25, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Beta Lab

                            Deal Size : $10.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth